-Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

Press/Media

Period11 Dec 2024

Media coverage

2

Media coverage

  • Title-Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletM2 PressWIRE
    Country/TerritoryUnited States
    Date11/12/24
    PersonsJohn Mascarenhas
  • Title-Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date11/12/24
    PersonsJohn Mascarenhas